### **CONFIDENTIAL** 1 (9)



Helsinki, 16 March 2020

#### Addressees

Registrants of JS\_di-TMPTTA EC 830-217-3 listed in the last Appendix of this decision

Date of submission for the jointly submitted dossier subject of a decision 30/10/2018

Registered substance subject to this decision, hereafter 'the Substance'

Substance name: Reaction products of acrylic acid with 2,2'-[oxybis(methylene)]bis[2-

ethylpropane-1,3-diol] EC number: 830-217-3 CAS number: 1393932-71-2

**Decision number:** [Please refer to the REACH-IT message which delivered this

communication (in format TPE-D-XXXXXXXXXXXXXXX/F)]

#### **DECISION ON A TESTING PROPOSAL**

Based on Article 40 of Regulation (EC) No 1907/2006 (REACH), ECHA requests that you submit the information listed below by the deadline of **21 June 2022**.

#### A. Requirements applicable to all the Registrants subject to Annex IX of REACH

- 1. Sub-chronic toxicity study (90-day), oral route (Annex IX, Section 8.6.2.; test method OECD TG 408) in rats with the Substance;
- 2. Pre-natal developmental toxicity study (Annex IX, Section 8.7.2.; test method OECD TG 414) in a first species (rat or rabbit), oral route with the Substance.

# Conditions to comply with the requests

Each addressee of this decision is bound by the requests for information corresponding to the REACH Annexes applicable to their own registered tonnage of the Substance at the time of evaluation of the jointly submitted dossier.

You have to comply with the requirements of Annexes VII, VIII and IX of REACH, if you have registered a substance at 100-1000 tpa.

The testing material used to perform the required studies must be selected and reported in accordance with the specifications prescribed in Appendix entitled Observations and technical guidance.

You must submit the information requested in this decision by the deadline indicated above in an updated registration dossier and also update the chemical safety report, where relevant, including any changes to classification and labelling, based on the newly generated information.

# **CONFIDENTIAL** 2 (9)



# **Appeal**

This decision can be appealed to the Board of Appeal of ECHA within three months of its notification. An appeal, together with the grounds thereof, has to be submitted to ECHA in writing. An appeal has suspensive effect and is subject to a fee. Further details are described under: <a href="http://echa.europa.eu/regulations/appeals">http://echa.europa.eu/regulations/appeals</a>.

Approved¹ under the authority of Christel Schilliger-Musset, Director of Hazard Assessment

-

<sup>&</sup>lt;sup>1</sup> As this is an electronic document, it is not physically signed. This communication has been approved according to ECHA's internal decision-approval process.

#### **CONFIDENTIAL** 3 (9)



# Appendix A: Reasons for the requirements applicable to all the Registrants subject to Annex IX of REACH

This decision is based on the examination of the testing proposals you submitted.

# 1. Sub-chronic toxicity study (90-day), oral route (Annex IX, Section 8.6.2.)

A sub-chronic toxicity study (90 day) is a standard information requirement in Annex IX, Section 8.6.2. to REACH.

You have submitted a testing proposal for a sub-chronic toxicity study (90 day) in rats by the oral route according to OECD TG 408 with the Substance.

ECHA requested your considerations for alternative methods to fulfil the information requirement for Sub-chronic toxicity (90-day): oral. ECHA notes that you provided your considerations concluding that there were no alternative methods which could be used to adapt the information requirement(s) for which testing is proposed. ECHA has taken these considerations into account.

As the dossier does not contain currently any sub-chronic toxicity study, ECHA considers that the proposed study is appropriate to fulfil the information requirement of Annex IX, Section 8.6.2. of the REACH Regulation.

You proposed testing by the oral route. Based on the information provided in the technical dossier and/or in the chemical safety report, ECHA agrees that the oral route - which is the preferred one as indicated in ECHA *Guidance on information requirements and chemical safety assessment* (version 6.0, July 2017) Chapter R.7a, Section R.7.5.4.3 - is the most appropriate route of administration. More specifically, the Substance is a liquid of very low vapour pressure and no uses with spray application are reported that could potentially lead to aerosols of inhalable size. Hence, the test must be performed by the oral route using the test method OECD TG 408.

You proposed testing in rats. ECHA agrees with your proposal.

According to Article 40(3)(a) of the REACH Regulation, you are requested to carry out the proposed test with the Substance.

# 2. Pre-natal developmental toxicity study (Annex IX, Section 8.7.2.) in a first species

A pre-natal developmental toxicity (PNDT) study (OECD TG 414) in one species is a standard information requirement under Annex IX, Section 8.7.2. to REACH.

You have submitted a testing proposal for a PNDT study according to OECD TG 414.

You provided your considerations concluding that there were no alternative methods which could be used to adapt the information requirement(s) for which testing is proposed. ECHA has taken these considerations into account.

As the dossier does not contain currently any PNDT study, ECHA considers that the proposed study is appropriate to fulfil the information requirement of Annex IX, Section 8.7.2. of the REACH Regulation.

# **CONFIDENTIAL** 4 (9)



You proposed testing with the rat as a first species. ECHA agrees with your proposal. The rat or rabbit is the preferred species under the OECD TG 414<sup>2</sup>.

You did not specify the route for testing. The Substance is a liquid with very low vapour pressure and no uses with spray application are reported that could potentially lead to aerosols of inhalable size. The oral route is the most appropriate route of administration to investigate reproductive toxicity<sup>3</sup>.

Under Article 40(3)(a) of the REACH Regulation, you are requested to carry out the proposed test with the Substance.

<sup>&</sup>lt;sup>2</sup> For the selection of the appropriate species you are advised to consult ECHA Guidance R.7a, Section R.7.6.2.3.2.

<sup>&</sup>lt;sup>3</sup> ECHA Guidance R.7a, Section R.7.6.2.3.2.

#### **CONFIDENTIAL** 5 (9)



#### Appendix B: Procedural history

ECHA started the testing proposal evaluation in accordance with Article 40(1) on 31 October 2018.

ECHA held a third party consultation for the testing proposals from 24 January 2019 until 11 March 2019. ECHA did not receive information from third parties.

For the purpose of the decision-making, this decision does not take into account any updates of registration dossiers after the date on which you were notified the draft decision according to Article 50(1) of the REACH.

ECHA notified you of the draft decision and invited you to provide comments within 30 days of the notification.

ECHA did not receive any comments within the 30-day notification period.

ECHA notified the draft decision to the competent authorities of the Member States for proposals for amendment.

As no amendments were proposed, ECHA adopted the decision under Article 51(3) of REACH.



#### Appendix C: Observations and technical guidance

- 1. This testing proposal examination decision does not prevent ECHA from initiating compliance checks at a later stage on the registrations present.
- 2. Failure to comply with the requests in this decision, or to otherwise fulfil the information requirements with a valid and documented adaptation, will result in a notification to the enforcement authorities of your Member State(s).
- 3. Test guidelines, GLP requirements and reporting

According to Article 13(3) of REACH, all new data generated as a result of this decision needs to be conducted according to the test methods laid down in a European Commission Regulation or according to international test methods recognised by the Commission or ECHA as being appropriate.

According to Article 13(4) of REACH ecotoxicological and toxicological tests and analyses shall be carried out according to the GLP principles (Directive 2004/10/EC) or other international standards recognised by the Commission or ECHA.

According to Article 10 (a) (vi) and (vii) of REACH, all new data generated as a result of this decision must be reported as study summaries, or as robust study summaries, if required under Annex I of REACH. See ECHA Practical Guide: 'How to report robust study summaries'<sup>4</sup>.

### 4. Test material

Selection of the test material(s) for UVCB substances

The registrants of the Substance are responsible for agreeing on the composition of the test material to be selected for carrying out the tests required by the present decision. The test material selected must be relevant for all the registrants of the Substance, i.e. it takes into account the variation in compositions reported by all members of the joint submission. The composition of the test material(s) must fall within the boundary composition(s) of the Substance.

While selecting the test material you must take into account the impact of each constituent/impurity on the test results for the endpoint to be assessed. For example, if a constituent/impurity of the Substance is known to have an impact on (eco)toxicity, the selected test material must contain that constituent/impurity. Any constituents that have harmonised classification and labelling according to the CLP Regulation (Regulation (EC) No 1272/2008) must be identified and quantified using the appropriate analytical methods.

The OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring, Number 11 [ENV/MC/CHEM(98)16] requires a careful identification of the test material and description of its characteristics. In addition, the Test Methods Regulation (EU) 440/2008, as amended by Regulation (EU) 2016/266, requires that "if the test method is used for the testing of a [...] UVCB [...] sufficient information on its composition should be made available, as far as possible, e.g. by the chemical identity of its constituents, their quantitative occurrence, and relevant properties of the constituents".

<sup>4</sup> https://echa.europa.eu/practical-guides

#### **CONFIDENTIAL** 7 (9)



In order to meet this requirement, all the constituents of the test material used for each test must be identified as far as possible. For each constituent the concentration value in the test material must be reported in the Test material section of the endpoint study record.

Technical Reporting of the test material for UVCB substances

The composition of the selected test material must be reported in the respective endpoint study record, under the Test material section. The composition must include all constituents of the test material and their concentration values. Without such detailed reporting, ECHA may not be able to confirm that the test material is relevant for the Substance and to all the registrants of the Substance.

Considering the specific characteristics of the Substance, constituents differing in terms of number of di(trimethylol)propane units, number of acrylate units and degree of esterification must be reported separately. You must also report their concentration values. The approach applied currently in the boundary composition is sufficiently detailed in this regard and should be used as a guide.

Technical instructions are available in the manual "How to prepare registration and PPORD dossiers" on the ECHA website<sup>5</sup>.

#### 5. List of references of the ECHA Guidance documents<sup>6</sup>

#### QSARs, read-across and grouping

Guidance on information requirements and chemical safety assessment, Chapter R.6 (version 1.0, May 2008), referred to as ECHA Guidance R.6 in this decision.

ECHA Read-across assessment framework (RAAF, March 2017)7

#### Physical-chemical properties

Guidance on information requirements and chemical safety assessment, Chapter R.7a (version 6.0, July 2017), referred to as ECHA Guidance R.7a in this decision.

#### Toxicology

Guidance on information requirements and chemical safety assessment, Chapter R.7a (version 6.0, July 2017), referred to as ECHA Guidance R.7a in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.7c (version 3.0, June 2017), referred to as ECHA Guidance R.7c in this decision.

#### Environmental toxicology and fate

Guidance on information requirements and chemical safety assessment, Chapter R.7a (version 6.0, July 2017), referred to as ECHA Guidance R.7a in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.7b (version 4.0, June 2017), referred to as ECHA Guidance R.7b in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.7c (version 3.0, June 2017), referred to as ECHA Guidance R.7c in this decision.

<sup>5</sup> https://echa.europa.eu/manuals

 $<sup>^{6}\</sup> https://echa.europa.eu/guidance-documents/guidance-on-information-requirements-and-chemical-safety-assessment$ 

https://echa.europa.eu/support/registration/how-to-avoid-unnecessary-testing-on-animals/grouping-of-substances-and-read-across

# **CONFIDENTIAL** 8 (9)



#### PBT assessment

Guidance on information requirements and chemical safety assessment, Chapter R.11 (version 3.0, June 2017), referred to as ECHA Guidance R.11 in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.16 (version 3.0, February 2016), referred to as ECHA Guidance R.16 in this decision.

# **CONFIDENTIAL** 9 (9)



Appendix D: List of the registrants to which the decision is addressed and the corresponding information requirements applicable to them

Registrant Name	Registration number	(Highest) Data requirements to be fulfilled

Note: where applicable, the name of a third party representative (TPR) may be displayed in the list of recipients whereas the decision is sent to the actual registrant.